Bristol Myers Squibb · 1 hour ago
Vice President, Drug Development Portfolio Strategy
Madison, NJ
Full-time
Onsite
Director/Executive
$306K/yr - $371K/yr
15+ years expBristol Myers Squibb is a leading biopharmaceutical company that is dedicated to transforming patients' lives through science. The Vice President of Drug Development Portfolio Strategy will lead the development and prioritization of investment strategies across multiple therapeutic areas, ensuring alignment with enterprise goals and guiding significant portfolio decisions.
BiotechnologyHealth CareMedicalPharmaceuticalPrecision Medicine
Responsibilities
Oversee disease area strategy development across all therapeutic areas for drug development to influence portfolio-level decisions
Partner with Drug Development Franchise Leads to ensure each disease assessment is grounded in a deep understanding of emerging science, competitive environment, and evolution of the landscape over the 10+ year horizon
Build capability for enabling development of disease plans that are robust, actionable, and competitively differentiated, implementing a consistent approach across teams
Lead drug development portfolio prioritization process, ensuring transparency and rigor in decisions
Drive alignment with key stakeholders including Enterprise Strategy and Research, Development and Commercial teams (RDC) to integrate disease strategies into therapeutic area strategies consistent with enterprise goals
Serve as a thought leader and strategic advisor to senior leadership on portfolio and investment decisions
Qualification
Required
Advanced degree (PhD, MD, PharmD, MBA or equivalent) in life sciences, business, or related field
Minimum 15 years of experience in drug development, strategic planning, or business development within the biopharmaceutical industry
Proven track record of leading portfolio strategy and investment decisions
Strong stakeholder management skills, including strategic cross-functional relationship building, project management, and the ability to influence decisions across all stakeholders including senior leadership and matrix teams
In-depth understanding of the pharmaceutical value chain, including R&D, regulatory requirements, knowledge of the competitive landscape, and market dynamics
Benefits
Health Coverage: Medical, pharmacy, dental, and vision care.
Wellbeing Support: Programs such as BMS Well-Being Account, BMS Living Life Better, and Employee Assistance Programs (EAP).
Financial Well-being and Protection: 401(k) plan, short- and long-term disability, life insurance, accident insurance, supplemental health insurance, business travel protection, personal liability protection, identity theft benefit, legal support, and survivor support.
Paid Time Off
US Exempt Employees: flexible time off (unlimited, with manager approval, 11 paid national holidays (not applicable to employees in Phoenix, AZ, Puerto Rico or Rayzebio employees)
Phoenix, AZ, Puerto Rico and Rayzebio Exempt, Non-Exempt, Hourly Employees: 160 hours annual paid vacation for new hires with manager approval, 11 national holidays, and 3 optional holidays
Unlimited paid sick time
Up to 2 paid volunteer days per year
Summer hours flexibility
Leaves of absence for medical, personal, parental, caregiver, bereavement, and military needs
An annual Global Shutdown between Christmas and New Years Day.
Company
Bristol Myers Squibb
At Bristol Myers Squibb, we work every day to transform patients’ lives through science.
10001+ employees
H1B Sponsorship
Bristol Myers Squibb has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (213)
2024 (278)
2023 (231)
2022 (180)
2021 (181)
2020 (169)
Funding
Current Stage
Public CompanyTotal Funding
$29.32BKey Investors
Venrock
2025-11-05Post Ipo Debt· $5.74B
2024-02-14Post Ipo Debt· $13B
2023-10-30Post Ipo Debt· $4.5B
Leadership Team
Charles Bancroft
CFO
Cristian Massacesi
Executive Vice President, Chief Medical Officer and Head of Development
Recent News
2025-12-30
BioWorld Financial Watch
2025-12-29
2025-12-25
Company data provided by crunchbase